Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SciSparcSPRC 45 EV-to-FCF is 0.17 as of Jul. 14, 2026, which is 19% below its 10-year median of 0.21. GuruFocus rates SPRC with a GF Score™ of 45/100 and a GF Value™ of $3.10 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 335 Biotechnology companies, SciSparc ranks better than 92.54% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, SciSparc's Enterprise Value is $-0.70 Mil.
SciSparc's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.14 Mil. Therefore, SciSparc's EV-to-FCF for today is 0.17.
The historical rank and industry rank for SciSparc's EV-to-FCF or its related term are showing as below:
SPRC'
s EV-to-FCF Range Over the Past 10 Years
Min: -0.7 Med: 0.21 Max: 0.71
Current: 0.17
During the past 13 years, the highest EV-to-FCF of SciSparc was 0.71. The lowest was -0.70. And the median was 0.21.
SPRC's EV-to-FCF is ranked better than 92.54% of 335
companies
in the Biotechnology industry
Industry Median: 15.34
vs SPRC: 0.17
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SciSparc's share price for today is $4.57.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SciSparc's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-3394.681.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
SciSparc EV-to-FCF Related Terms
SciSparc EV-to-FCF Historical Data
* Premium members only.
The historical data trend for SciSparc's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SciSparc's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SciSparc EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SciSparc's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where SciSparc's EV-to-FCF falls into.
SciSparc's current Enterprise Value is $-0.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SciSparc's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SciSparc (SPRC) has a EV-to-FCF of 0.17 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on SciSparc and its competitors. This is 19% below median its historical median of 0.21. According to the industry distribution chart, SciSparc ranks #25 out of 335 companies in the Biotechnology industry, placing it in the top 7.5%.
Is SciSparc's EV-to-FCF too high?
SciSparc's current EV-to-FCF of 0.17 is 19% below median its 10-year median of 0.21. The Biotechnology industry median EV-to-FCF is 15.34. SciSparc's value of 0.17 is 98.9% below this industry median. Based on the distribution chart, SciSparc ranks #25 out of 335 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SciSparc has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SciSparc's EV-to-FCF compare to BIXT and BGMS?
According to the Biotechnology industry distribution chart, SciSparc ranks #25 out of 335 companies for EV-to-FCF. This places SciSparc in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 15.34. SciSparc's value of 0.17 is 98.9% below this benchmark. While the company's 10-year median is 0.21 vs. the industry median of 15.34, SciSparc has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.34, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SciSparc's current EV-to-FCF of 0.17 is 98.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on SciSparc and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SciSparc's current EV-to-FCF is 0.17, which is 19% below median its own 10-year median of 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SciSparc stock overvalued right now?
Based on GuruFocus' analysis, SciSparc (SPRC) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.10, compared to a current price of $4.57 — trading 47.4% above its estimated fair value. The current EV-to-FCF is 0.17, which is 19% below median its 10-year median of 0.21 and 98.9% below the Biotechnology industry median of 15.34. SciSparc's overall GF Score™ is 45/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For SciSparc (SPRC), the current EV-to-FCF is 0.17 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SciSparc (SPRC) Overvalued in 2026?
Based on GuruFocus' analysis, SciSparc stock appears to be overvalued.
The current stock price of $4.57 is trading 47.4% above its estimated GF Value™ of $3.10.
GuruFocus considers SciSparc to be Significantly Overvalued.
Key valuation signals for SPRC:
EV-to-FCF: 0.17 (19% below median its 10-year median of 0.21)
GF Value™: $3.10 vs. price of $4.57 (47.4% above fair value)
Industry Position: 98.9% below the Biotechnology median (#25 of 335)
No single metric tells the full story. See the SPRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
45GF Score
Get the complete analysis for SPRC
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRC has been successfully added to your 
